EGFR and non-small cell lung carcinoma: Interestingly, prolonged administration of gefitinib (EGFR TKI) in NSCLC cells increased ROS levels and correlated with the occurrence of epithelial–mesenchymal transition (EMT), a well-established characteristic of tumors displaying drug resistance [25].